BERLIN (EGMN) - The final report from the NPC-9901 trial supports the current practice of treating regionally advanced nasopharyngeal carcinoma using chemoradiotherapy, but also confirms a worrisome trend. This regimen "can substantially improve locoregional control, but we also have to inform patients there is a possible subtle increase in risk of noncancer death, and this might narrow the survival gain," lead author Dr. Anne Lee said at the joint congress of the European Cancer Organization and...